SMU-B is the orally active inhibitor for ALK (IC50c-ros oncogene 1 (ROS1), c-MET (IC50=1.87 nM) and AXL (IC50=28.9 nM). SMU-B inhibits the proliferation of MKN45, H1993 and H441 with IC50s of 0.02 µM, 1.58 µM and 2.82 µM, respectively. SMU-B exhibits antitumor efficacy in mouse models[1][2].
